Search Lavipharm.com

 

Our History

Historical Highlights

1911 Establishment of Lavipharm, a pharma company by the Lavidas’ family
1914 Launch of Digitaline, an innovative cardiovascular product, in Greece
1958 Launch of Nitroglycerin Controlled Release tablets, in Greece
1976 New era begins under the management of Dr. Athanase Lavidas
1977 Collaboration with L’Oreal – first to sell cosmetics through pharmacies, in Greece
1979 Inauguration of Plant for the production of drugs & cosmetics
1985 Establishment of R&D department focused on drug delivery technologies
1989 First international operation center established in Paris
1989 First to launch AVON products in Greece establishing door-to-door channel
1992 Joint Ventures with Synthelabo and L’Oreal Cosmetique Active
Completion of a dedicated transdermal systems production unit in Greece
Launch of proprietary dermocosmetic brand CASTALIA
1993 Establishment of state-of-the-art wholesaling and distribution center
1995 Listing on the Athens Stock Exchange
Entrance in the international market, launch of proprietary nitroglycerin transdermal system in Italy and France
CASTALIA dermocosmetic brand launched internationally
1996 Acquisition of US-based R&D unit specialized in TDDS
Launch of patented acne epidermal patch, worldwide, by L’Oréal
1998 Exclusive licensing rights to manufacture and market Betadine® brand in Greece

2000 Acquisition of R&D companies (France and the USA) with expertise in SCF technologies

2001  Establishment of a new subsidiary, Pharma PLUS, focusing on creating a nationwide pharmacy network under a common brand
2006 FDA approval of proprietary fentanyl patch
2007 Fentanyl patch first launch in Greece
2008 Fentanyl patch launch in Germany
2010 Regulatory approval to market fentanyl patch in 20 countries
2011 Establishment of operation center in Italy
2012 Entry in the Urology Market in Greece
2014 Entry in the Rare Diseases’ market
2015 Manufacturing rights for rivastigmine patch
2019 Manufacturing rights for clonidine patch
2020 Exclusive distribution agreement with Zentiva in Greece
2021 Telemaque Lavidas takes helm of Lavipharm Group
Lavipharm is celebrating 110 Years Innovation in Health
Today Fentanyl patch consecutive launches in the EU, Latin America and Asia